BioCentury
ARTICLE | Clinical News

TZP-102: Phase IIb discontinued

December 24, 2012 8:00 AM UTC

Tranzyme discontinued the double-blind, U.S. and Polish Phase IIb DIGEST trial in patients with Type I or II diabetes and a history of symptoms of gastroparesis after a planned interim futility analysis examining patient responsiveness to thrice-daily 10 mg TZP-102 or placebo given before meals for 12 weeks showed insufficient efficacy at the end of weeks 4 and 8. Tranzyme declined to provide details or next steps for the TZP-102 program, but said the results were consistent with a prior Phase IIb trial in which there was a large placebo effect and no treatment effect. ...